CORRECTED-Lundbeck says FDA accepts review of schizophrenia drug
(Corrects 2nd paragraph to say Feb. 28 is FDA decision deadline, not a meeting)
COPENHAGEN, Sept 12 (Reuters) - Danish pharmaceutical group Lundbeck said the U.S. Food and Drug Administration was to review a resubmission of a new drug application for treating schizophrenia.
A new FDA deadline to make a decision regarding the treatment, aripiprazole depot formulation, had been set for Feb. 28, Lundbeck said on Wednesday in a statement with Japanese firm Otsuka Pharmaceutical Co with whom it is in partnership, following initial deficiencies in the application.
Lundbeck has co-development and co-commercialisation rights to aripiprazole depot formulation in North and Latin America as well as Europe, Australia and some other countries.
(Reporting by Copenhagen Newsroom; Editing by Dan Lalor and Gerald E. McCormick)
- Tweet this
- Share this
- Digg this
- Russia can run on empty for a year if sanctions block new bonds
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- Apple says celebrity photo breach targeted, not due to its systems
- Actress Jennifer Lawrence contacts authorities after nude photos hacked
- Nasty, brutish and artsy? Neanderthal hashtag engraving found